Ratings
0
Nobody has rated this yet. Be the first!
Works
13
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Hepatotoxicity with combination of vemurafenib and ipilimumab
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Nivolumab plus ipilimumab in advanced melanoma
